This trial is completed!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Spontaneous Reactivation of Hepatitis B
and you are
between 18 and 65
years old
Phase
-
The phase for this study is not defined.
Show me locations

The purpose

The relevant data will be prospectively collected included patient demographics, clinical, all laboratory variables including virological tests, genotyping by direct sequencing, abdominal ultrasound, and upper gastrointestinal (GI) endoscopy. Trans jugular liver biopsy (TJLB) and hepatic venous pressure gradient (HVPG) will be done in patients when it was not evident whether the underlying liver disease was chronic based on clinical, biochemical, radiological investigations, and upper GI endoscopy. Severity of the liver disease will be assessed by Child-Turcotte Pugh score (CTP) and model for end stage liver disease (MELD) score.

Provided treatments

  • Drug: Tenofovir + Telbivudine
  • Drug: Tenofovir
Tris trial is registered with FDA with number: NCT01732224. The sponsor of the trial is Institute of Liver and Biliary Sciences, India and it is looking for 69 volunteers for the current phase.
Official trial title:
A Prospective Randomized Controlled Study to Compare the Efficacy of Combined Tenofovir Plus Telbuvidine vs Tenofovir Alone in Patients With Spontaneous Reactivation of Hepatitis B.